Vibegron

• Overactive Bladder
• Urge Urinary Incontinence
• Urinary Frequency and Urgency

Vibegron (brand name Gemtesa) is a selective beta-3 adrenergic receptor agonist used to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in adults. By activating relaxation pathways in detrusor smooth muscle, it increases functional bladder capacity and reduces urgency episodes without the dry mouth, constipation, and cognitive side effects that limit anticholinergic therapy. Approved by the FDA in 2020, vibegron expanded the beta-3 agonist class beyond mirabegron and offers a particularly attractive profile for older adults in whom anticholinergic burden is a major concern.

Mechanism of Action

The detrusor muscle expresses several adrenergic receptor subtypes, with beta-3 receptors predominating in the bladder wall. Agonism of these receptors during the storage phase of micturition activates Gs-coupled signaling, increases intracellular cyclic AMP, and produces detrusor relaxation, allowing the bladder to fill to a larger volume before urgency is felt and reducing involuntary detrusor contractions. Vibegron is highly selective for beta-3 over beta-1 and beta-2 receptors (selectivity ratio approximately 9000-fold over beta-1), which limits cardiovascular effects compared with less selective agents. Vibegron does not appreciably block muscarinic receptors, sparing cognition, salivation, gastrointestinal motility, and accommodation. It is metabolized minimally by cytochrome P450 enzymes (mainly CYP3A4 with a minor contribution), which simplifies drug interactions, although it does inhibit P-glycoprotein and modestly raises digoxin exposure through this mechanism. The Urology Care Foundation overview of overactive bladder provides patient context.

Clinical Use

Vibegron is appropriate for patients with overactive bladder symptoms who have not responded to behavioral therapy alone, who cannot tolerate the anticholinergic burden of muscarinic antagonists such as oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, or trospium, or whose cognitive risk profile (older adults, dementia, polypharmacy with other anticholinergics) makes anticholinergics undesirable. Anticholinergic burden has been linked in observational studies to incident dementia, which has shifted prescribing patterns toward beta-3 agonists in older adults. Within the beta-3 class, vibegron competes with mirabegron; the two have similar efficacy but vibegron has not shown clinically meaningful blood pressure increases in pivotal trials, which can be advantageous for patients with hypertension or cardiovascular disease. First-line therapy remains behavioral, including timed voiding, fluid management (particularly evening fluid restriction for nocturia), bladder training, and pelvic floor exercises. For men with concurrent benign prostatic hyperplasia symptoms, an alpha-blocker such as tamsulosin may be combined with caution because of urinary retention risk. The American Urological Association overactive bladder guideline outlines current management. See our genitourinary care page.

How to Take It

Vibegron is taken as a 75 mg tablet once daily, with or without food, at approximately the same time each day. Tablets can be swallowed whole or, for patients with swallowing difficulties, crushed and mixed with one tablespoon of applesauce; if crushed, the mixture should be consumed within 10 minutes and followed by a glass of water to ensure complete dose delivery. No titration is required, and the same dose applies regardless of age (within renal limits). If a dose is missed, skip it and resume the next day rather than doubling. Most patients begin to notice fewer urgency episodes and incontinence events within two weeks, with maximal benefit by eight to twelve weeks. Continue behavioral measures, especially fluid pacing and reducing bladder irritants such as caffeine, alcohol, carbonated beverages, and artificial sweeteners, alongside the medication. Storage is at room temperature; keep the original container closed and away from moisture.

Monitoring and Follow-Up

No routine laboratory monitoring is required. Useful tracking measures include a 24- or 72-hour bladder diary documenting void frequency, urgency episodes, and incontinence events; many clinicians repeat this at four and twelve weeks to objectively gauge response. Validated questionnaires such as the Overactive Bladder Questionnaire (OAB-q) or the King's Health Questionnaire can supplement diary data. Blood pressure should be recorded at baseline and at follow-up, although vibegron has not shown a clinically significant pressor effect in trials. For patients on digoxin, check a serum digoxin level before starting vibegron and again within one to two weeks, since vibegron raises digoxin AUC by roughly 20 percent through P-glycoprotein inhibition; dose adjustment of digoxin may be required to keep levels in the therapeutic window. A baseline post-void residual is reasonable in patients with possible bladder outlet obstruction (men with BPH, prior pelvic surgery, neurogenic bladder), and our lab panels article covers the standard renal panel that informs dosing decisions.

Special Populations

No dose adjustment is required for eGFR 15 mL/min or above; vibegron is not recommended for end-stage renal disease or dialysis because of insufficient data. Mild and moderate hepatic impairment do not require adjustment, but severe impairment (Child-Pugh C) is not recommended. Older adults, who represent the majority of overactive bladder patients, often benefit most from the avoidance of anticholinergic effects on cognition, balance, and bowel function; vibegron has emerged as a preferred option in this group based on safety considerations. Pregnancy and lactation data are limited; use only when clearly needed. Pediatric use is not established. In men with significant outlet obstruction, vibegron may increase the risk of urinary retention, especially when combined with antimuscarinic agents; baseline assessment of voiding function and PSA is reasonable. Patients with a history of urinary retention should use vibegron with particular caution.

Behavioral Adjuncts and Long-Term Management

Pharmacotherapy works best as part of a multimodal approach to overactive bladder. Behavioral interventions remain the foundation: bladder training (gradually extending the time between voids), urge suppression techniques (pelvic floor contraction, distraction, deep breathing during urgency episodes), pelvic floor muscle exercises (Kegels) ideally taught by a pelvic floor physical therapist, and fluid management (typically 48-64 ounces daily, weighted toward earlier in the day for nocturia control). Bladder irritants vary by individual but commonly include caffeine, alcohol, carbonated beverages, artificial sweeteners, citrus, tomato-based foods, and spicy foods; an elimination-and-rechallenge approach can identify personal triggers without unnecessary dietary restriction. Constipation worsens overactive bladder by mechanical pressure on the bladder, so regular bowel habits with adequate fiber and hydration support symptom control. Weight loss in overweight patients reduces overactive bladder symptoms in observational studies, likely through reduced intra-abdominal pressure. For patients with refractory symptoms despite optimized behavioral measures and at least two pharmacologic trials, third-line options include intravesical onabotulinumtoxinA injection, percutaneous tibial nerve stimulation (a series of in-office sessions), and sacral neuromodulation (an implanted device); referral to urology is appropriate at this stage. Combination therapy with vibegron plus an antimuscarinic such as solifenacin has shown additive benefit in trials and is reasonable when monotherapy is insufficient, with attention to retention risk. Sleep optimization helps nocturia management, since fragmented sleep amplifies urgency perception; treating coexisting sleep apnea often improves nocturia. Elderly patients particularly benefit from a fall-prevention assessment, since rushing to the bathroom is a common fall scenario, especially at night; nightlights, clear pathways, and appropriate footwear reduce risk. Our practical guide to fall prevention outlines a thorough approach. Long-term adherence is improved by setting realistic expectations: most patients see meaningful but not complete symptom improvement, and the goal is reduction in bother rather than total elimination of urgency.

When to Contact Your Doctor

Call promptly for an inability to urinate or significant difficulty initiating a stream, sudden lower abdominal pain with bladder fullness, or new flank pain that may suggest urinary retention or upper tract involvement. Allergic reactions including facial or throat swelling, hives, or breathing difficulty constitute an emergency. Sustained elevations in blood pressure, palpitations, or new edema should be reported. Patients on digoxin who develop nausea, visual changes (yellow-green halos around lights), confusion, or arrhythmia symptoms should be assessed for digoxin toxicity related to the interaction. New or worsening urinary tract infection symptoms (burning, frequency disproportionate to baseline, hematuria, fever) warrant evaluation, since UTIs can mimic or worsen overactive bladder symptoms.

If overactive bladder is interfering with sleep, work, social activities, or quality of life, contact us or schedule a visit to discuss whether vibegron or another therapy is the right next step.